Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics, Inc. (KROS) was reported as having 1,813,870 shares beneficially owned by BlackRock Portfolio Management LLC, equal to 9.1% of the class, as of September 30, 2026. The reported position carried sole voting power over 1,575,150 shares and sole dispositive power over 1,813,870 shares; shared voting and dispositive power were both zero. BlackRock says these figures cover certain business units of BlackRock, Inc. and its subsidiaries and affiliates, excluding units whose ownership is disaggregated. Various persons may receive dividends or sale proceeds, but no one person's interest exceeded 5% of outstanding common shares.
Keros Therapeutics, Inc. (KROS) expects to receive a $20 million development milestone payment under its elritercept license agreement with partner Takeda, following dosing of the first patient in the Phase 3 ELRiSE MF trial. The trial compares elritercept with placebo in patients with myelofibrosis and anemia receiving concurrent ruxolitinib therapy.
Keros expects to distribute 25% of the payment’s net cash proceeds to stockholders following receipt. The global license agreement, effective January 16, 2025, covers rights outside mainland China, Hong Kong and Macau. Keros received a $200 million upfront cash payment in February 2025 and is eligible for development, commercial and sales milestones with potential to exceed $1.1 billion, as well as tiered royalties on net sales. Elritercept is being developed for cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis.
Keros Therapeutics, Inc. (KROS) announced that the first patient was dosed in its Phase 2 trial of rinvatercept in Duchenne muscular dystrophy (DMD). The open-label, multi-cohort basket trial’s primary objective is to assess safety and tolerability in late-ambulatory and early non-ambulatory patients. Initial data are expected in the first half of 2027. Keros describes rinvatercept as a ligand trap designed to inhibit the biological effects of myostatin and activin A, which it describes as negative regulators of muscle and bone mass and strength.
Keros Therapeutics, Inc. (KROS) has filed a shelf registration to offer, from time to time, up to $350.0 million of common stock, preferred stock, debt securities and/or warrants, including a sales agreement prospectus for up to $100.0 million of common stock under an at-the-market program with Leerink Partners LLC. The $100.0 million ATM capacity is part of, not in addition to, the $350.0 million shelf. Keros is a clinical-stage biopharmaceutical company focused on protein therapeutics targeting dysfunctional transforming growth factor-beta signaling, with lead product candidates rinvatercept and elritercept, the latter licensed ex‑China to Takeda. As a smaller reporting company, it plans to use any net proceeds for general corporate purposes such as R&D, clinical trials, working capital, potential in-licensing or acquisitions, capital expenditures, and possible debt repayment or security repurchases.
Keros Therapeutics, Inc. (KROS) announced that its board of directors approved a new stock repurchase program for up to $5 million of its common stock, to be implemented after receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under a license agreement for elritercept.
As of June 30, 2026, Keros reported $257.6 million in cash and cash equivalents. Based on current operating plans, and after giving effect to the $20 million milestone and the $5 million stock repurchase, Keros anticipates this cash balance will fund operating and capital expenditure requirements into the second half of 2028.
Keros Therapeutics, Inc. (KROS) reported that Annita Tanini, Corp. Controller & VP, Finance, sold 1,224 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share. The company states these were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units, and Ms. Tanini now holds 45,144 shares directly.
Keros Therapeutics, Inc. (KROS) reported that Chief Scientific Officer Lorena Raquel Lerner sold 3,568 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share, in automatic "sell-to-cover" transactions for tax withholding on vesting RSUs. Following these sales, she held 27,559 shares of common stock directly.
Keros Therapeutics, Inc. (KROS) reported a Form 4 for Chief Legal Officer Esther Cho. On 2026-08-18, she sold 4,485 shares of common stock at a weighted average price of $10.29 per share in automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units. The sales occurred at prices ranging from $10.14 to $10.50 and were not at her discretion. After these sales, she directly holds 35,770 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. (KROS) director Charles W. Newton reported selling 551 shares of common stock on August 18, 2026 in a transaction coded as an open market or private sale. The weighted average sale price was $10.30 per share, with individual trades between $10.16 and $10.49. After this sale, he directly holds 12,114 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.